Premium
Low Malignant Potential Ovarian Tumours: A Review of 175 Consecutive Cases
Author(s) -
Buttini Melissa,
Nicklin James L.,
Crandon Alex
Publication year - 1997
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.1997.tb02228.x
Subject(s) - medicine , lymphadenectomy , stage (stratigraphy) , disease , lymph node , adjuvant therapy , ovarian cancer , ovary , surgery , randomized controlled trial , cancer , oncology , chemotherapy , paleontology , biology
Summary: Epithelial ovarian tumours of low malignant potential (LMP) are known to have a generally good prognosis, although there is not universal agreement on all aspects of treatment. We report a series of 175 patients with LMP ovarian tumours referred to the Queensland Centre for Gynaecological Cancer between January, 1982 and December, 1993. Stage I disease accounted for 142 cases, with only 1 patient dead from disease at 293 months. Twenty nine patients in this group had conservative surgery with 1 recurrence only (in the contralateral ovary) giving a recurrence rate of 3.5%. Survival and treatment data for other stages are presented, and the current literature reviewed. It is suggested that early stage disease may be treated conservatively depending upon the patient's desire to retain reproductive capacity. While adjuvant therapy is not recommended, long‐term follow‐up is indicated. More advanced disease should be debulked to the smallest practical volume. The role of lymphadenectomy has been questioned, as survival has not been shown to be affected by treatment decisions made as a result of knowing the lymph node status. Whilst some centres give platinum‐based adjuvant therapy, the evidence that it is beneficial is not supported by any prospective randomized trials.